Five Discovery launches regenerative neurology program using non-hallucinogenic neuroplastogens inspired by 5-MeO-DMT

Five Discovery announces its launch as a biotechnology company developing small-molecule therapeutics for regenerative neurology, aiming to restore dysfunctional brain circuits in neurodegenerative disease and brain injury. The company frames its pipeline as “non-hallucinogenic neuroplastogens” inspired by the neurobiological mechanisms of 5-MeO-DMT, designed to preserve neuroplastic and anti-inflammatory effects while eliminating hallucinogenic activity for scalable clinical development. Five Discovery’s lead program targets Levodopa-Induced Dyskinesia (LID), a complication of long-term levodopa therapy in Parkinson’s disease, and positions LID as an initial regulatory entry point with potential for orphan-drug designation and FDA-validated endpoints. The company also plans to expand into Parkinson’s Disease and additional CNS indications and notes it will present at the Psychedelic Therapeutics and Drug Development Conference in New Orleans, Louisiana on February 26-27, 2026.